JP2022546317A5 - - Google Patents

Info

Publication number
JP2022546317A5
JP2022546317A5 JP2022511290A JP2022511290A JP2022546317A5 JP 2022546317 A5 JP2022546317 A5 JP 2022546317A5 JP 2022511290 A JP2022511290 A JP 2022511290A JP 2022511290 A JP2022511290 A JP 2022511290A JP 2022546317 A5 JP2022546317 A5 JP 2022546317A5
Authority
JP
Japan
Prior art keywords
hla
cells
mhc class
expressing
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022511290A
Other languages
English (en)
Japanese (ja)
Other versions
JP7728747B2 (ja
JP2022546317A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047639 external-priority patent/WO2021041316A1/en
Publication of JP2022546317A publication Critical patent/JP2022546317A/ja
Publication of JP2022546317A5 publication Critical patent/JP2022546317A5/ja
Priority to JP2025134675A priority Critical patent/JP2025186232A/ja
Application granted granted Critical
Publication of JP7728747B2 publication Critical patent/JP7728747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022511290A 2019-08-23 2020-08-24 Cd24発現細胞およびそれらの用途 Active JP7728747B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025134675A JP2025186232A (ja) 2019-08-23 2025-08-13 Cd24発現細胞およびそれらの用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891180P 2019-08-23 2019-08-23
US62/891,180 2019-08-23
PCT/US2020/047639 WO2021041316A1 (en) 2019-08-23 2020-08-24 Cd24 expressing cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025134675A Division JP2025186232A (ja) 2019-08-23 2025-08-13 Cd24発現細胞およびそれらの用途

Publications (3)

Publication Number Publication Date
JP2022546317A JP2022546317A (ja) 2022-11-04
JP2022546317A5 true JP2022546317A5 (cg-RX-API-DMAC7.html) 2023-09-01
JP7728747B2 JP7728747B2 (ja) 2025-08-25

Family

ID=72432999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022511290A Active JP7728747B2 (ja) 2019-08-23 2020-08-24 Cd24発現細胞およびそれらの用途
JP2025134675A Withdrawn JP2025186232A (ja) 2019-08-23 2025-08-13 Cd24発現細胞およびそれらの用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025134675A Withdrawn JP2025186232A (ja) 2019-08-23 2025-08-13 Cd24発現細胞およびそれらの用途

Country Status (7)

Country Link
US (1) US20230025289A1 (cg-RX-API-DMAC7.html)
EP (1) EP4017508A1 (cg-RX-API-DMAC7.html)
JP (2) JP7728747B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220068222A (cg-RX-API-DMAC7.html)
AU (1) AU2020336302A1 (cg-RX-API-DMAC7.html)
CA (1) CA3148370A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041316A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505592A (ja) * 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
CN110869494B (zh) 2017-06-12 2025-02-18 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
CA3123102A1 (en) 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2021072302A1 (en) * 2019-10-10 2021-04-15 New York Stem Cell Foundation, Inc. Modified stem cells and methods of use thereof
JP2023511965A (ja) * 2020-01-23 2023-03-23 カンステム バイオテック カンパニー リミテッド Off-the-shelf幹細胞および免疫細胞、それを含む薬学的組成物
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
WO2022232569A1 (en) * 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods to improve t cell efficacy and safety by modulating mediators of phagocytosis
US20240226164A1 (en) * 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
AU2022325231A1 (en) * 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
US20260053851A1 (en) 2021-08-11 2026-02-26 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
EP4479084A1 (en) 2022-02-14 2024-12-25 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
CN116804185A (zh) * 2022-03-25 2023-09-26 士泽生物医药(苏州)有限公司 一种通用型细胞及其制备方法
WO2023215455A1 (en) * 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
WO2024097313A1 (en) * 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Methods for producing t cell therapy products
CN118147077B (zh) * 2022-12-07 2025-09-26 士泽生物医药(苏州)有限公司 一种表达gsn的通用型细胞及其制备方法
CN118207166A (zh) * 2022-12-16 2024-06-18 士泽生物医药(苏州)有限公司 一种通用型细胞及其制备方法
WO2024169917A1 (zh) * 2023-02-16 2024-08-22 士泽生物医药(苏州)有限公司 通用型细胞及其制备方法
CN121311581A (zh) * 2023-06-05 2026-01-09 士泽生物医药(苏州)有限公司 一种免疫豁免性诱导性多能干细胞分化的神经细胞及其应用
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
CN121046319A (zh) * 2024-05-20 2025-12-02 南京奇迹生物科技有限公司 一种降低t细胞免疫原性的方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
US8273570B2 (en) 2000-05-16 2012-09-25 Riken Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20030223972A1 (en) 2002-02-15 2003-12-04 Goldman Steven A. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
US20050101014A1 (en) 2002-07-11 2005-05-12 Keirstead Hans S. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
ATE418346T1 (de) 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
KR20130099253A (ko) 2005-06-22 2013-09-05 제론 코포레이션 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
EP2028268A1 (en) 2007-08-20 2009-02-25 Université Libre De Bruxelles Generation of neuronal cells from pluripotent stem cells
WO2009057111A2 (en) 2007-10-29 2009-05-07 Hadasit Medical Research Services & Development Limited Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
US8227247B2 (en) 2007-12-20 2012-07-24 Wisconsin Alumni Research Foundation Method of generating myelinating oligodendrocytes
US8728812B2 (en) 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US9683215B2 (en) 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
CN102325878A (zh) 2008-12-23 2012-01-18 斯特姆塞尔思加利福尼亚有限公司 少突胶质前体细胞的靶向细胞群及制备与使用方法
US8507274B2 (en) 2009-02-06 2013-08-13 President And Fellows Of Harvard College Compositions and methods for promoting the generation of definitive endoderm
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
US9057053B2 (en) 2010-01-19 2015-06-16 The Board Of Trustees Of The Leland Stanford Junior University Direct conversion of cells to cells of other lineages
ES2826445T3 (es) 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
US9193951B2 (en) 2010-10-26 2015-11-24 Case Western Reserve University Differentiation method for production of glial cell populations
CA2829804A1 (en) 2011-03-29 2012-10-04 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
CA2831609C (en) 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
KR101966208B1 (ko) 2011-07-21 2019-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 환자로부터 유도 만능 줄기 세포들로부터의 심근 세포 및 그 사용 방법
US8951798B2 (en) 2011-10-13 2015-02-10 Wisconsin Alumni Research Foundation Generation of cardiomyocytes from human pluripotent stem cells
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2013184809A1 (en) 2012-06-05 2013-12-12 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
JP6756610B2 (ja) 2013-04-26 2020-09-16 メモリアル スローン ケタリング キャンサー センター 多分化能細胞および多能性細胞の分化を方向付けることによって発生させる皮質介在ニューロンおよびその他のニューロン細胞
JP6873705B2 (ja) 2014-05-22 2021-05-19 ニューヨーク ステム セル ファウンデーション インコーポレイテッド 多能性幹細胞由来の機能性オリゴデンドロサイト、ならびにその作製方法及び使用方法
WO2015182765A1 (ja) 2014-05-30 2015-12-03 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
US9765299B2 (en) 2014-09-10 2017-09-19 Wisconsin Alumni Research Foundation Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
CA2995634A1 (en) 2015-08-15 2017-02-23 Asterias Biotherapeutics, Inc. Stem cell-derived oligodendrocyte progenitor cells for the treatment of white matter stroke
CA3016575A1 (en) 2016-03-03 2017-09-08 New York Stem Cell Foundation, Inc. Microglia derived from pluripotent stem cells and methods of making and using the same
WO2017172976A1 (en) 2016-03-29 2017-10-05 The Regents Of The University Of California Methods for promoting oligodendrocyte regeneration and remyelination
WO2018093681A1 (en) 2016-11-15 2018-05-24 Neuralstem, Inc. Multipotent neural stem cells that express platelet derived growth factor (pdgf) receptor and methods of use thereof
KR20240095477A (ko) 2017-01-13 2024-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
EP3601528A4 (en) 2017-03-20 2021-05-05 Washington University Cells and methods of uses and making the same
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
AU2019305585A1 (en) 2018-07-17 2021-01-28 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells

Similar Documents

Publication Publication Date Title
JP2022543112A5 (cg-RX-API-DMAC7.html)
US20230062612A1 (en) Safety switches for regulation of gene expression
JP6502544B2 (ja) Hla g改変された細胞および方法
Wu et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
US20230272429A1 (en) Modification of blood type antigens
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CA2956385A1 (en) Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
HK1218232A1 (zh) 使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因
CN114026225A (zh) 安全的免疫隐形细胞
JP2025061188A (ja) キメラサイトカイン受容体
JP2022512674A (ja) 人工トランス活性化因子による選択
Zheng et al. Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes
JP2020535834A (ja) 遺伝子修飾されたベータ細胞による糖尿病の治療
IL301534A (en) A method for preparing effector cells with the desired specificity
US11723987B2 (en) Double suicide gene vector systems for stem cells
KR102906951B1 (ko) 내인성 항원 제시 기전을 이용한 저면역원성 줄기세포 및 이의 제조 방법
WO2025181283A1 (en) Cell
CN120826463A (zh) 使用工程化细胞的癌症免疫疗法
WO2021207671A1 (en) Treating autoimmune diseases with genetically modified cells
CN117343962A (zh) 免疫兼容型人多能干细胞、其制备方法及应用
Cicciarelli et al. Prospects for Designing ‘Universal’Stem Cell Lines
KR20230043906A (ko) 영양 장애형 표피 수포증의 치료약
Gornalusse et al. 81.“Semi-Universal Donor Stem Cells” That Express a Single Class I Human Leukocyte Antigen (HLA) A* 0201 Can Present Peptides to Allorestricted CD8+ T-Cells